Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: PNC129
MIFTS: 69

Pancreatic Adenocarcinoma

Categories: Cancer diseases, Endocrine diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Pancreatic Adenocarcinoma

About this section

MalaCards integrated aliases for Pancreatic Adenocarcinoma:

Name: Pancreatic Adenocarcinoma 12 29 6 15 17
Adenocarcinoma of the Pancreas 12
Pancreas Adenocarcinoma 12

Classifications:

MalaCards categories:
Global: Cancer diseases
Anatomical: Endocrine diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 12 DOID:4074
NCIt 50 C8294
UMLS 72 C0281361
Sources

Summaries for Pancreatic Adenocarcinoma

About this section
Disease Ontology : 12 A pancreatic carcinoma that derives from epithelial cells of glandular origin.

MalaCards based summary : Pancreatic Adenocarcinoma, also known as adenocarcinoma of the pancreas, is related to pancreatic cancer and adenocarcinoma, and has symptoms including abdominal pain, pruritus and icterus. An important gene associated with Pancreatic Adenocarcinoma is TP53 (Tumor Protein P53), and among its related pathways/superpathways are Signaling by GPCR and Innate Immune System. The drugs Propofol and Desflurane have been mentioned in the context of this disorder. Affiliated tissues include pancreas, liver and lymph node, and related phenotypes are Decreased viability and Decreased viability

Sources

Related Diseases for Pancreatic Adenocarcinoma

About this section

Diseases related to Pancreatic Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 565)
# Related Disease Score Top Affiliating Genes
1 pancreatic cancer 34.8 VEGFA TP53 STAT3 SRC SMAD4 PIK3CA
2 adenocarcinoma 33.9 VEGFA TP53 SMAD4 PTGS2 PIK3CA MUC4
3 pancreas disease 32.4 TP53 SMAD4 KRAS HRAS AKT1
4 exanthem 32.3 KRAS HRAS ERBB2 EGFR
5 cholangiocarcinoma 32.2 TP53 STAT3 SMAD4 PTGS2 PIK3CA MUC4
6 intrahepatic cholangiocarcinoma 32.2 TP53 MUC4 KRAS EGFR CTNNB1
7 pancreatic ductal carcinoma 32.1 VEGFA TP53 SMAD4 CDKN2A
8 cystadenocarcinoma 32.1 VEGFA TP53 PIK3CA HRAS ERBB2 AKT1
9 adenoma 32.0 TP53 SMAD4 PTGS2 KRAS GNAS CTNNB1
10 peutz-jeghers syndrome 32.0 TP53 SMAD4 CTNNB1 BRCA2
11 in situ carcinoma 31.9 TP53 ERBB2 EGFR CDKN2A
12 mucinous adenocarcinoma 31.9 KRAS EGFR CDKN2A
13 breast cancer 31.9 VEGFA TP53 STAT3 SRC SMAD4 PTGS2
14 hepatocellular carcinoma 31.9 VEGFA TP53 STAT3 SMAD4 PTGS2 PIK3CA
15 bile duct cancer 31.8 VEGFA TP53 EGFR CCND1
16 colorectal cancer 31.8 VEGFA TP53 STAT3 SRC SMAD4 PTGS2
17 acinar cell carcinoma 31.8 TP53 SMAD4 CTNNB1 BRCA2
18 gastrointestinal stromal tumor 31.8 VEGFA TP53 KRAS EGFR CDKN2A CCND1
19 ovarian serous cystadenocarcinoma 31.8 TP53 PIK3CA HRAS ERBB2 AKT1
20 lynch syndrome 31.7 TP53 KRAS EGFR CTNNB1 CDKN2A CCND1
21 familial adenomatous polyposis 31.7 TP53 SMAD4 PTGS2 KRAS CTNNB1 CCND1
22 breast adenocarcinoma 31.7 TP53 SMAD4 PIK3CA KRAS ERBB2 EGFR
23 squamous cell carcinoma 31.7 VEGFA TP53 SMAD4 PTGS2 PIK3CA HRAS
24 esophageal cancer 31.7 VEGFA TP53 STAT3 SMAD4 PTGS2 PIK3CA
25 glioblastoma 31.7 VEGFA TP53 SRC PIK3CA HRAS ERBB2
26 barrett esophagus 31.7 TP53 PTGS2 ERBB2 CDKN2A CCND1
27 glioblastoma multiforme 31.6 VEGFA TP53 STAT3 PIK3CA ERBB2 EGFR
28 cervical cancer 31.6 VEGFA TP53 STAT3 SMAD4 PTGS2 PIK3CA
29 prostate cancer 31.6 VEGFA TP53 STAT3 SRC PTGS2 PIK3CA
30 adenosquamous carcinoma 31.6 TP53 PIK3CA MUC4 KRAS EGFR
31 serous cystadenocarcinoma 31.6 VEGFA TP53 PIK3CA HRAS ERBB2 AKT1
32 gastric cancer 31.6 VEGFA TP53 SMAD4 PTGS2 PIK3CA KRAS
33 ovary adenocarcinoma 31.5 TP53 PIK3CA KRAS HRAS ERBB2
34 colorectal adenocarcinoma 31.5 VEGFA TP53 PTGS2 KRAS HRAS EGFR
35 gallbladder cancer 31.5 TP53 PTGS2 PIK3CA KRAS ERBB2 EGFR
36 transitional cell carcinoma 31.5 TP53 PTGS2 HRAS ERBB2 EGFR CDKN2A
37 bladder urothelial carcinoma 31.5 TP53 PIK3CA KRAS HRAS ERBB2 CTNNB1
38 suppression of tumorigenicity 12 31.5 TP53 SMAD4 PIK3CA HRAS CTNNB1 AKT1
39 gastrointestinal system disease 31.5 VEGFA TP53 STAT3 PTGS2 KRAS HRAS
40 breast ductal carcinoma 31.4 TP53 ERBB2 EGFR CTNNB1 CCND1
41 myeloma, multiple 31.4 VEGFA TP53 STAT3 KRAS HRAS CDKN2A
42 cervical adenocarcinoma 31.4 TP53 PTGS2 ERBB2 CDKN2A
43 endometrial cancer 31.4 VEGFA TP53 STAT3 PIK3CA KRAS HRAS
44 tongue cancer 31.4 TP53 CTNNB1 CDKN2A CCND1
45 ovarian cancer 31.4 VEGFA TP53 STAT3 PIK3CA KRAS ERBB2
46 li-fraumeni syndrome 31.4 TP53 EGFR CDKN2A BRCA2
47 gastric adenocarcinoma 31.4 VEGFA TP53 STAT3 SMAD4 PTGS2 PIK3CA
48 mantle cell lymphoma 31.4 TP53 STAT3 CDKN2A CCND1 AKT1
49 lung cancer susceptibility 3 31.4 VEGFA TP53 STAT3 SRC SMAD4 PTGS2
50 leukemia, acute myeloid 31.3 TP53 STAT3 KRAS HRAS AKT1

Graphical network of the top 20 diseases related to Pancreatic Adenocarcinoma:



Diseases related to Pancreatic Adenocarcinoma
Sources

Symptoms & Phenotypes for Pancreatic Adenocarcinoma

About this section

UMLS symptoms related to Pancreatic Adenocarcinoma:


abdominal pain, pruritus, icterus

GenomeRNAi Phenotypes related to Pancreatic Adenocarcinoma according to GeneCards Suite gene sharing:

26 (show all 17)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 10.92 EGFR PIK3CA HRAS KRAS
2 Decreased viability GR00106-A-0 10.92 KRAS
3 Decreased viability GR00221-A-1 10.92 AKT1 CDKN2A EGFR PIK3CA HRAS KRAS
4 Decreased viability GR00221-A-2 10.92 AKT1 PIK3CA HRAS KRAS
5 Decreased viability GR00221-A-3 10.92 AKT1 CDKN2A ERBB2 HRAS
6 Decreased viability GR00221-A-4 10.92 AKT1 CDKN2A EGFR ERBB2 PIK3CA
7 Decreased viability GR00301-A 10.92 KRAS
8 Decreased viability GR00381-A-1 10.92 KRAS
9 Decreased viability GR00402-S-2 10.92 AKT1 CDKN2A EGFR ERBB2 PIK3CA HRAS
10 Decreased viability in esophageal squamous lineage GR00235-A 10.1 BRCA2 CCND1 CDKN2A CTNNB1 ERBB2 GNAS
11 Decreased cell migration GR00055-A-1 9.98 AKT1 CTNNB1 EGFR HRAS KRAS MAP2K2
12 Decreased focal adhesion (FA) area, decreased FA length, decreased FA mean intensity, increased number of small and round FAs, increased FA abundance GR00210-A 9.8 CTNNB1 EGFR ERBB2 HRAS VEGFA
13 Decreased viability with paclitaxel GR00179-A-1 9.56 EGFR ERBB2 SRC
14 Decreased viability with paclitaxel GR00179-A-3 9.56 EGFR
15 Increased cell migration GR00055-A-3 9.55 CTNNB1 EGFR HRAS KRAS PIK3CA
16 Increased cell viability after pRB stimulation GR00230-A-1 9.26 AKT1 EGFR ERBB2 MAP2K2
17 Reduced mammosphere formation GR00396-S 9.23 CCND1 EGFR GNAS HRAS KRAS PTGS2

MGI Mouse Phenotypes related to Pancreatic Adenocarcinoma:

46 (show all 28)
# Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 10.58 AKT1 BRCA2 CCND1 CDKN2A CTNNB1 EGF
2 growth/size/body region MP:0005378 10.57 AKT1 BRCA2 CCND1 CDKN2A CTNNB1 EGF
3 behavior/neurological MP:0005386 10.56 AKT1 BRCA2 CCND1 CDKN2A CTNNB1 ERBB2
4 cellular MP:0005384 10.55 AKT1 BRCA2 CCND1 CDKN2A CTNNB1 EGFR
5 cardiovascular system MP:0005385 10.53 AKT1 CCND1 CDKN2A CTNNB1 EGFR ERBB2
6 integument MP:0010771 10.53 AKT1 BRCA2 CCND1 CDKN2A CTNNB1 EGF
7 homeostasis/metabolism MP:0005376 10.5 AKT1 BRCA2 CCND1 CDKN2A CTNNB1 EGFR
8 digestive/alimentary MP:0005381 10.49 BRCA2 CCND1 CDKN2A CTNNB1 EGF EGFR
9 immune system MP:0005387 10.46 AKT1 BRCA2 CCND1 CDKN2A CTNNB1 EGF
10 mortality/aging MP:0010768 10.46 AKT1 BRCA2 CCND1 CDKN2A CTNNB1 EGFR
11 embryo MP:0005380 10.45 AKT1 BRCA2 CDKN2A CTNNB1 EGFR ERBB2
12 craniofacial MP:0005382 10.43 CCND1 CTNNB1 EGFR ERBB2 GNAS HRAS
13 neoplasm MP:0002006 10.43 AKT1 BRCA2 CCND1 CDKN2A CTNNB1 EGFR
14 hematopoietic system MP:0005397 10.42 AKT1 BRCA2 CCND1 CDKN2A CTNNB1 EGFR
15 nervous system MP:0003631 10.39 AKT1 BRCA2 CCND1 CDKN2A CTNNB1 EGFR
16 muscle MP:0005369 10.31 AKT1 CDKN2A CTNNB1 EGFR ERBB2 GNAS
17 normal MP:0002873 10.31 AKT1 BRCA2 CCND1 CTNNB1 EGF EGFR
18 liver/biliary system MP:0005370 10.26 AKT1 CDKN2A CTNNB1 EGFR GNAS KRAS
19 adipose tissue MP:0005375 10.24 AKT1 EGFR GNAS MAP2K2 PIK3CA PTGS2
20 limbs/digits/tail MP:0005371 10.24 BRCA2 CTNNB1 EGFR ERBB2 GNAS KRAS
21 reproductive system MP:0005389 10.16 AKT1 BRCA2 CCND1 CDKN2A CTNNB1 EGF
22 no phenotypic analysis MP:0003012 10.13 CDKN2A CTNNB1 EGFR GNAS HRAS KRAS
23 hearing/vestibular/ear MP:0005377 10.06 CTNNB1 EGFR GNAS KRAS MAP2K2 TP53
24 renal/urinary system MP:0005367 10.02 CTNNB1 EGFR GNAS HRAS KRAS PTGS2
25 respiratory system MP:0005388 10 AKT1 CCND1 CDKN2A CTNNB1 EGFR ERBB2
26 skeleton MP:0005390 9.91 AKT1 BRCA2 CCND1 CDKN2A CTNNB1 EGFR
27 pigmentation MP:0001186 9.85 CDKN2A CTNNB1 EGFR KRAS SRC TP53
28 vision/eye MP:0005391 9.44 CCND1 CDKN2A CTNNB1 EGF EGFR KRAS
Sources

Drugs & Therapeutics for Pancreatic Adenocarcinoma

About this section

Drugs for Pancreatic Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 352)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
2
Desflurane Approved Phase 4 57041-67-5 42113
3
Ciprofloxacin Approved, Investigational Phase 4 85721-33-1 2764
4
Metronidazole Approved Phase 4 443-48-1 4173
5 Anesthetics Phase 4
6 Anesthetics, General Phase 4
7 Anesthetics, Inhalation Phase 4
8 Antitubercular Agents Phase 4
9
Docetaxel Approved, Investigational Phase 2, Phase 3 114977-28-5 148124
10
Dexamethasone Approved, Investigational, Vet_approved Phase 2, Phase 3 50-02-2 5743
11
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 2, Phase 3 1177-87-3
12
Curcumin Approved, Experimental, Investigational Phase 3 458-37-7 969516
13
Celecoxib Approved, Investigational Phase 3 169590-42-5 2662
14
Darbepoetin alfa Approved, Investigational Phase 2, Phase 3 11096-26-7, 209810-58-2
15
Enoxaparin Approved Phase 2, Phase 3 9005-49-6 772
16
Irinotecan Approved, Investigational Phase 2, Phase 3 100286-90-6, 97682-44-5 60838
17
leucovorin Approved Phase 2, Phase 3 58-05-9 143 6006
18
Ifosfamide Approved Phase 3 3778-73-2 3690
19
Ethanol Approved Phase 3 64-17-5 702
20
Levoleucovorin Approved, Investigational Phase 3 68538-85-2
21
Heparin Approved, Investigational Phase 3 9005-49-6 46507594 772
22
Dalteparin Approved Phase 3 9005-49-6
23
Clopidogrel Approved Phase 3 113665-84-2, 120202-66-6 60606
24
Aspirin Approved, Vet_approved Phase 3 50-78-2 2244
25
Calcium Approved, Nutraceutical Phase 2, Phase 3 7440-70-2 271
26
Folic acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
27
Rubitecan Investigational Phase 3 91421-42-0
28
Imidacloprid Vet_approved Phase 2, Phase 3 105827-78-9 86418
29
tipifarnib Investigational Phase 3 192185-72-1 159324
30
Irofulven Investigational Phase 3 158440-71-2
31 BB 1101 Phase 2, Phase 3
32 Cyclooxygenase Inhibitors Phase 3
33 Cyclooxygenase 2 Inhibitors Phase 3
34 Gastrins Phase 3
35 ON 01910 Phase 3
36 Antineoplastic Agents, Phytogenic Phase 3
37 Tubulin Modulators Phase 3
38 Antimitotic Agents Phase 3
39
Isophosphamide mustard Phase 3 0
40 Calcium, Dietary Phase 2, Phase 3
41 Central Nervous System Depressants Phase 3
42 Anti-Infective Agents, Local Phase 3
43 Hematinics Phase 3
44
asparaginase Phase 3
45 Folate Phase 3
46 Vitamin B9 Phase 3
47 Fibrinolytic Agents Phase 3
48 Heparin, Low-Molecular-Weight Phase 3
49 Anticoagulants Phase 3
50 calcium heparin Phase 3

Interventional clinical trials:

(show top 50) (show all 770)
# Name Status NCT ID Phase Drugs
1 Endoscopic Ultrasound-guided Celiac Plexus Neurolysis (EUS-CPN) With Alcohol in Patients With Locally Advanced and Unresectable Pancreatic Adenocarcinoma: A Randomized Pilot Study Completed NCT00578279 Phase 4 dehydrated alcohol
2 A Pharmacokinetic Study of Adjuvant Capecitabine in Patients Who Have Undergone Proximal Pancreatico-duodenectomy for Resection of Pancreatic Adenocarcinoma Completed NCT00854477 Phase 4 capecitabine
3 Endoscopic Radiofrequency Ablation for Malignant Biliary Obstruction Completed NCT01758341 Phase 4
4 Resectable Pancreatic Adenocarcinoma - Does the Type of Anesthesia Have an Impact on Circulating Tumor Cells? Recruiting NCT02335151 Phase 4 Desflurane
5 The Effect of Gemcitabine Plus Nab-paclitaxel as Secondary Chemotherapy in Advanced Pancreatic Cancer Recruiting NCT03401827 Phase 4 Chemotherapy (Gemcitabine + nab-paclitaxel)
6 A Dose Escalation Safety Study of Locally-Delivered (Intra-Arterial) Gemcitabine in Unresectable Adenocarcinoma of the Pancreas Active, not recruiting NCT02237157 Phase 4 Gemcitabine, local delivery
7 A Pilot Study of Gut Microbiome Modulation to Enable Efficacy of Checkpoint-based Immunotherapy in Pancreatic Adenocarcinoma Not yet recruiting NCT03891979 Phase 4 Antibiotics and Pembrolizumab
8 Exocrine Pancreatic Insufficiency in Pancreatic Cancer: Evaluating the Need and Efficacy of Pancreatic Enzyme Replacement Therapy Withdrawn NCT01401387 Phase 4
9 Phase III Randomized Study Of Gemcitabine Versus Gemcitabine-Oxaliplatine In Patients With Locally Advanced Or Metastatic Pancreatic Carcinoma Unknown status NCT00075452 Phase 3 gemcitabine hydrochloride;oxaliplatin
10 A Multicentre, Randomized, Open Label, Phase III Study of Gemcitabine Versus FOLFOX in the First Line Setting for Metastatic Pancreatic Cancer Patients Using Human Equilibrative Nucleoside Transporter 1 (hENT1) Biomarker Testing. Unknown status NCT01586611 Phase 3 5FU, leucovorin, oxaliplatin;Gemcitabine
11 Phase II Randomisee Dans Les Adenocarcinomes Metastatiques Du Pancreas: Gemox Et Gemox Simplifie. [GEMOX] Unknown status NCT00268411 Phase 3 gemcitabine hydrochloride;oxaliplatin
12 Randomized Phase II/III Trial Comparing Folririnox Association [Oxaliplatin / Irinotecan / LV5FU2] Versus Gemcitabine in First Line of Chemotherapy in Metastatics Pancreas Cancers Patients Unknown status NCT00112658 Phase 2, Phase 3 fluorouracil;gemcitabine hydrochloride;irinotecan hydrochloride;leucovorin calcium;oxaliplatin
13 Phase III Randomized Study of RFS 2000 (9-Nitro-Camptothecin, 9-NC) Versus Most Appropriate Therapy in Refractory Pancreatic Cancer Patients Unknown status NCT00005870 Phase 3 fluorouracil;gemcitabine hydrochloride;mitomycin C;rubitecan
14 Phase III Randomized Study of RFS 2000 (9-Nitro-Camptothecin, 9-NC) Versus Gemcitabine HCl in Chemonaive Pancreatic Cancer Patients Unknown status NCT00005869 Phase 3 gemcitabine hydrochloride;rubitecan
15 A Phase III Randomized, Controlled Study to Evaluate the Safety and Efficacy of PANVACâ„¢-VF in Combination With GM-CSF Versus Best Supportive Care or Palliative Chemotherapy in Patients With Metastatic (Stage IV) Adenocarcinoma of the Pancreas Who Have Failed a Gemcitabine-Containing Chemotherapy Regimen Unknown status NCT00088660 Phase 3
16 Phase III Randomized Study of RFS 2000 (9-Nitro-Camptothecin, 9-NC) Versus 5-Fluorouracil (5-FU) in Pancreatic Cancer Patients That Have Progressive Disease Following Gemcitabine HCl Treatment Unknown status NCT00005871 Phase 3 fluorouracil;rubitecan
17 Phase III Randomized, Double-blind Study Comparing Gemcitabine and Sorafenib or a Placebo in Patients With Locally Advanced or Metastatic Cancer of the Pancreas. Unknown status NCT00541021 Phase 3 gemcitabine hydrochloride;sorafenib tosylate
18 Phase III Trial of Gemcitabine, Curcumin and Celebrex in Patients With Advance or Inoperable Pancreatic Cancer Unknown status NCT00486460 Phase 3 Gemcitabine;Curcumin;Celebrex
19 Resection of the Nerve Plexus on the Right Half of Celiac and SMA Associated With Extended Pancreatoduodenectomy in the Surgical Treatment for Adenocarcinoma of the Head of Pancreas Unknown status NCT02514928 Phase 3
20 Phase II Study: Neoadjuvant Gemcitabine, Docetaxel and Capecitabine Followed by Neoadjuvant Radiation Therapy With Gemcitabine and Capecitabine in the Treatment of Stage II and III Pancreatic Adenocarcinoma Unknown status NCT01065870 Phase 2, Phase 3 Neoadjuvant gemcitabine, capecitabine, and docetaxel;Gemcitabine, capecitabine, docetaxel followed by radiotherapy
21 CROSSFIRE Trial: Crossatlantic Randomized Controlled Trial Comparing Outcome in Survival After Systemic Plus Focal Therapy for Inoperable Pancreatic Carcinoma: Radiotherapy Versus Irreversible Electroporation Unknown status NCT02791503 Phase 2, Phase 3
22 A Prospective, Multi-centric, Phase â…¢, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Second-Line Adjuvant Therapy With Nab-Paclitaxel Plus Gemcitabine (AG) Versus Oxaliplatin Plus Folinic Acid and Fluorouracil (OFF) for Gemcitabine-Refractory Pancreatic Cancer After Curative Resection Unknown status NCT02506842 Phase 3 nab-paclitaxel;gemcitabine;oxaliplatin;folinic acid;fluorouracil
23 A Randomized Phase III Study of Weekly ABI-007 Plus Gemcitabine Versus Gemcitabine Alone in Patients With Metastatic Adenocarcinoma of the Pancreas Completed NCT00844649 Phase 3 Albumin-bound paclitaxel (ABI-007);Gemcitabine
24 Phase III Trial Of Irofulven Vs. 5-Fluorouracil In Patients With Gemcitabine-Refractory Advanced Pancreatic Adenocarcinoma Completed NCT00033735 Phase 3 fluorouracil;Irofulven
25 European Study Group For Pancreatic Cancer - Trial 3 Completed NCT00058201 Phase 3 fluorouracil;gemcitabine hydrochloride;leucovorin calcium
26 A Phase III Study of Pre and Post Chemoradiation 5-FU vs. Pre and Post Chemoradiation Gemcitabine for Postoperative Adjuvant Treatment of Resected Pancreatic Adenocarcinoma Completed NCT00003216 Phase 3 fluorouracil;gemcitabine hydrochloride
27 Randomized Phase II-III Trial of Post-operative Treatment of Pancreatic Adenocarcinoma: Gemcitabine Versus PEFG Followed by Radiochemotherapy With Concomitant Continuous Infusion of 5-fluorouracil Completed NCT00960284 Phase 2, Phase 3 capecitabine;cisplatin;epirubicin hydrochloride;fluorouracil;gemcitabine hydrochloride
28 A Prospective, Randomized Trial of Extended Lymphadenectomy in the Management of Resectable Pancreatic Cancer Completed NCT00003049 Phase 3 fluorouracil;leucovorin calcium
29 A Randomized, Multicenter, Double-blind, Placebo-controlled, Phase 3 Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine, in the First Line Treatment of Patients With Metastatic Pancreatic Adenocarcinoma Completed NCT02436668 Phase 3 Ibrutinib;Gemcitabine;Nab-paclitaxel
30 Prospective, Randomized, Controlled, Double-Blind, Multi-National, Multi-Center Study of G17DT Immunogen in Combination With Gemcitabine Versus Placebo in Combination With Gemcitabine in Previously Untreated Subjects With Locally Advanced (Nonresectable Stage II and III), Recurrent Disease Following Primary Resection, or Metastatic (Stage IV) Adenocarcinoma of the Pancreas (Protocol No. PC4) Completed NCT00044031 Phase 3
31 Randomized Multicenter Phase III Study in Patients With Locally Advanced Adenocarcinoma of the Pancreas: Gemcitabine With or Without Chemoradiotherapy and With or Without Erlotinib. Intergroup Study Completed NCT00634725 Phase 3 capecitabine;erlotinib hydrochloride;gemcitabine hydrochloride
32 A Phase III Randomized Open-Label Study Comparing Gemcitabine Plus Cetuximab (IMC-C225) Versus Gemcitabine As First-Line Therapy Of Patients With Advanced Pancreas Cancer Completed NCT00075686 Phase 3 gemcitabine hydrochloride
33 Non Resectable But Non Metastatic Adenocarcinoma of the Exocrine Pancreas Non Resecables. Randomised Phase III: Initial Radiochimiotherapy (5-FU, Cisplatine, 60 GY Radiotherapy) Followed by Gemcitabine Versus Gemcitabine Alone Completed NCT00416507 Phase 3 fluorouracil;gemcitabine hydrochloride;liposomal cisplatin
34 A Randomized Phase 3 Study of the Efficacy and Safety of Glufosfamide Compared With Best Supportive Care in Metastatic Pancreatic Adenocarcinoma Previously Treated With Gemcitabine Completed NCT00099294 Phase 3 Glufosfamide
35 A Randomized, Controlled Trial of Intraoperative Celiac Plexus Neurolysis for Patients With Operable (Resectable and Unresectable) Pancreatic and Periampullary Cancer Completed NCT00806611 Phase 3
36 Gemcitabine Plus Capecitabine Versus Gemcitabine Alone In Advanced Pancreatic Cancer. A Randomized Phase III Trial Completed NCT00030732 Phase 3 Gemcitabine + Capecitabine;Gemcitabine alone
37 Infusional 5-Fluorouracil With or Without Cisplatin and With or Without Chronomodulation Against Locally-Advanced or Metastatic Pancreatic Cancer. A Multicenter Randomized Phase III Trial. Completed NCT00003029 Phase 3 cisplatin;fluorouracil
38 A Randomized, Double-Blind, Phase III Study of the Efficacy and Safety of Gemcitabine in Combination With TH-302 Compared With Gemcitabine in Combination With Placebo in Previously Untreated Subjects With Metastatic or Locally Advanced Unresectable Pancreatic Adenocarcinoma Completed NCT01746979 Phase 3 TH-302;Gemcitabine;Placebo (5 percent dextrose - D5W)
39 A Phase III Multicenter Randomized Clinical Trial Comparing Gemcitabine Alone Or In Combination With Capecitabine For The Treatment Of Patients With Advanced Pancreatic Cancer Completed NCT00032175 Phase 3 capecitabine;gemcitabine hydrochloride
40 A Phase III, Double-Blind, Placebo Controlled Trial of Gemcitabine Plus Placebo Versus Gemcitabine Plus R115777 in Patients With Advanced Pancreatic Cancer Completed NCT00005648 Phase 3 Gemcitabine with R115777;Gemcitabine with Placebo
41 A Phase III, Randomized Study of Gemcitabine (Fixed-Dose Rate Infusion) and Oxaliplatin (NSC 266046) Versus Gemcitabine (Fixed-Dose Rate Infusion) Versus Gemcitabine (30-Minute Infusion) in Pancreatic Carcinoma Completed NCT00058149 Phase 3 gemcitabine hydrochloride;oxaliplatin
42 Randomized Controlled Study: Comparison Between Extended and Standard Pancreatoduodenectomy Completed NCT00679913 Phase 3
43 A Prospective, Phase III, Controlled, Multicentre, Randomised Clinical Trial Comparing Combination Gemcitabine and Capecitabine Therapy With Concurrent and Sequential Chemoimmunotherapy Using a Telomerase Vaccine in Locally Advanced and Metastatic Pancreatic Cancer [TELOVAC] Completed NCT00425360 Phase 3 capecitabine;gemcitabine hydrochloride
44 Essai Randomise Comparant Deux Stategies De Chimiotherapie Dans Les Cancers Pancreatiques Avances: LV5FU2 Simplifie + Cisplatine Suivi de Gemcitabine, Versus Gemcitabine Suivi de LV5FU2 Simplifie + Cisplatine en Can de Progression Completed NCT00303758 Phase 3 cisplatin;fluorouracil;gemcitabine hydrochloride;leucovorin calcium
45 A Randomized Phase III Trial Of Gemcitabine Plus Bevacizumab (NSC#704865 IND#7621) Versus Gemcitabine Plus Placebo In Patients With Advanced Pancreatic Cancer Completed NCT00088894 Phase 3 gemcitabine hydrochloride
46 Randomized Phase II/III Study Comparing Gemcitabine Followed by Gemcitabine Plus Concomitant Radiation (50.4 Gy) Versus Control After Curative Pancreaticoduodenectomy for Pancreatic Head Cancer Completed NCT00064207 Phase 2, Phase 3 gemcitabine hydrochloride
47 A Randomized Phase III Study Of Gemcitabine In Combination With Radiation Therapy Versus Gemcitabine Alone In Patients With Localized, Unresectable Pancreatic Cancer Completed NCT00057876 Phase 3 Gemcitabine
48 A Prospective, Randomized Trial Of Simultaneous Pancreatic Cancer Treatment With Enoxaparin and ChemoTherapy (PROSPECT) Completed NCT00785421 Phase 2, Phase 3 enoxaparin;chemotherapy with LMWH - enoxaparin;only chemotherapy
49 Randomized Trial of Conventional Covered Self Expandable Metallic Stent Versus Paclitaxel Eluting Covered Self Expandable Metallic Stent in Unresectable Malignant Bile Duct Obstruction Completed NCT00453076 Phase 3
50 A Phase III, Multi-center, Randomized, Controlled Study to Compare the Efficacy and Safety of Gemcitabine Alone vs. ON 01910.Na Combined With Gemcitabine in Patients With Previously Untreated Metastatic Pancreatic Cancer Completed NCT01360853 Phase 3 ON 01910.Na;Gemcitabine;Gemcitabine

Search NIH Clinical Center for Pancreatic Adenocarcinoma

Inferred drug relations via UMLS 72 / NDF-RT 51 :


Mitomycin
Sources

Genetic Tests for Pancreatic Adenocarcinoma

About this section

Genetic tests related to Pancreatic Adenocarcinoma:

# Genetic test Affiliating Genes
1 Pancreatic Adenocarcinoma 29
Sources

Anatomical Context for Pancreatic Adenocarcinoma

About this section

MalaCards organs/tissues related to Pancreatic Adenocarcinoma:

41
Pancreas, Liver, Lymph Node, T Cells, Lung, Endothelial, Testes
Sources

Publications for Pancreatic Adenocarcinoma

About this section

Articles related to Pancreatic Adenocarcinoma:

(show top 50) (show all 6648)
# Title Authors PMID Year
1
Efficacy of Docetaxel and Oxaliplatin Regimen as a Second-Line Therapy for Patients with Advanced Pancreatic Adenocarcinoma. 38
29797144 2019
2
Survival and prognostic factors in patients with pancreatic squamous cell carcinoma. 38
31118133 2019
3
A Qualitative Review of Neoadjuvant Chemotherapy in Resectable Pancreatic Adenocarcinoma. 38
31425483 2019
4
Status of 5-Year Survivors of the Whipple Procedure for Pancreatic Adenocarcinoma. 38
31327451 2019
5
CT perfusion and diffusion-weighted MR imaging of pancreatic adenocarcinoma: can we predict tumor grade using functional parameters? 38
30428264 2019
6
Robotic-assisted versus laparoscopic left pancreatectomy at a high-volume, minimally invasive center. 38
30421076 2019
7
Biomarkers to diagnose metastatic breast carcinoma to the pancreas: A case report and update. 38
31087784 2019
8
Time to Adjuvant Systemic Therapy Following Pancreatic Cancer Resection and Effect on Outcome. 38
31404024 2019
9
Duration of chemotherapy prior to chemoradiation affects survival outcomes for resected stage I-II or unresected stage III pancreatic cancer. 38
31183965 2019
10
Needle tract seeding following endoscopic ultrasound-guided fine-needle aspiration for pancreatic cancer: a report of two cases. 38
31382964 2019
11
Abilities of berberine and chemically modified berberines to interact with metformin and inhibit proliferation of pancreatic cancer cells. 38
31047842 2019
12
Screening for Pancreatic Cancer: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. 38
31386140 2019
13
Chemotherapy response of pancreatic cancer by diffusion-weighted imaging (DWI) and intravoxel incoherent motion DWI (IVIM-DWI) in an orthotopic mouse model. 38
30825012 2019
14
Lentivirus-mediated RNA interference targeting programmed death receptor ligand 1 increases the immunologic anti-tumor effect of dendritic cell vaccination against pancreatic cancer in SCID-hu mice. 38
31423221 2019
15
Significance of Examined Lymph Node Number in Accurate Staging and Long-term Survival in Resected Stage I-II Pancreatic Cancer-More is Better? A Large International Population-based Cohort Study. 38
31425290 2019
16
Preoperative Prediction of Futile Surgery in Patients with Radiologically Resectable or Borderline Resectable Pancreatic Adenocarcinoma. 38
31425643 2019
17
Familial pancreatic adenocarcinoma: A retrospective analysis of germline genetic testing in a French multicentre cohort. 38
31432501 2019
18
Isolated metastatic pancreatic adenocarcinoma to the uterine cervix: A case report. 38
31334322 2019
19
Acute kidney injury associated with lymphangitic carcinomatosis. 38
31384444 2019
20
Phosphodiesterase 10A IgG: A novel biomarker of paraneoplastic neurologic autoimmunity. 38
31315972 2019
21
Relevance of positive resection margins in ductal pancreatic adenocarcinoma and prognostic factors. 38
31395275 2019
22
A prospective, multi-institution assessment of irreversible electroporation for treatment of locally advanced pancreatic adenocarcinoma: initial outcomes from the AHPBA pancreatic registry. 38
30737097 2019
23
Comparative effectiveness of primary tumor resection in patients with stage III pancreatic adenocarcinoma. 38
31370893 2019
24
Correction to: Phase Ib/II study of gemcitabine, nab-paclitaxel, and pembrolizumab in metastatic pancreatic adenocarcinoma. 38
31020607 2019
25
Alternate Week Gemcitabine and Capecitabine: An Effective Treatment for Patients With Pancreatic Adenocarcinoma. 38
31268983 2019
26
National Trends in Centralization of Surgical Care and Multimodality Therapy for Pancreatic Adenocarcinoma. 38
31420860 2019
27
18F-FDG PET/CT in pancreatic adenocarcinoma: A role at initial imaging staging? 38
31402332 2019
28
Adjuvant chemotherapy versus chemoradiation in high-risk pancreatic adenocarcinoma: A propensity score-matched analysis. 38
31414566 2019
29
Perioperative Gemcitabine + Erlotinib Plus Pancreaticoduodenectomy for Resectable Pancreatic Adenocarcinoma: ACOSOG Z5041 (Alliance) Phase II Trial. 38
31418130 2019
30
Proton Radiotherapy for Isolated Local Recurrence of Primary Resected Pancreatic Ductal Adenocarcinoma. 38
31147994 2019
31
Potentially Curable Pancreatic Adenocarcinoma: ASCO Clinical Practice Guideline Update. 38
31180816 2019
32
Contemporary Review of Borderline Resectable Pancreatic Ductal Adenocarcinoma. 38
31409042 2019
33
Potentially Curable Pancreatic Adenocarcinoma: ASCO Clinical Practice Guideline Update Summary. 38
31306038 2019
34
Pancreatic fat necrosis in a 10-year-old girl: A case report and review of the literature. 38
31423621 2019
35
Superparamagnetic iron-oxide-enhanced diffusion-weighted magnetic resonance imaging for the diagnosis of intrapancreatic accessory spleen. 38
31420705 2019
36
Extrahepatic Malignancies After Treatment with Direct Antiviral Agents for Chronic HCV Infection. 38
31407252 2019
37
Two-dimensional Texture Analysis Based on CT Images to Differentiate Pancreatic Lymphoma and Pancreatic Adenocarcinoma: A Preliminary Study. 38
30193819 2019
38
Randomized phase II trial of survivin 2B peptide vaccination for patients with HLA-A24-positive pancreatic adenocarcinoma. 38
31218770 2019
39
Significance of radiographic splenic vessel involvement in the pancreatic ductal adenocarcinoma of the body and tail of the gland. 38
31093997 2019
40
PUM1 knockdown prevents tumor progression by activating the PERK/eIF2/ATF4 signaling pathway in pancreatic adenocarcinoma cells. 38
31395860 2019
41
Anti-Apoptotic and Anti-Oxidant Proteins in Glioblastomas: Immunohistochemical Expression of Beclin and DJ-1 and Its Correlation with Prognosis. 38
31434323 2019
42
Exogenous Melatonin Up-Regulates Expression of CD62L by Lymphocytes in Aged Mice under Inflammatory and Non-Inflammatory Conditions. 38
30887869 2019
43
Implications of Prolonged Time to Pancreaticoduodenectomy After Neoadjuvant Chemoradiation. 38
31401247 2019
44
Outcomes of duodenal stenting: Experience in a French tertiary center with 220 cases. 38
31401023 2019
45
AJCC 7th edition staging classification is more applicable than AJCC 8th edition staging classification for invasive IPMN. 38
31387646 2019
46
Quantitative Elastography Versus Fine-needle Aspiration by Endoscopic Ultrasound for the Assessment of Pancreatic Solid Masses. 38
29521724 2019
47
Pathologic tumor response to neoadjuvant therapy in borderline resectable pancreatic cancer. 38
31176601 2019
48
The impact of extent of pancreatic and venous resection on survival for patients with pancreatic cancer. 38
31230959 2019
49
Enhancing Nab-Paclitaxel Delivery Using Microbubble-Assisted Ultrasound in a Pancreatic Cancer Model. 38
31356090 2019
50
LINC00346 promotes pancreatic cancer progression through the CTCF-mediated Myc transcription. 38
31391552 2019
Sources

Variations for Pancreatic Adenocarcinoma

About this section

ClinVar genetic disease variations for Pancreatic Adenocarcinoma:

6 (show top 50) (show all 403)
# Gene Variation Type Significance SNP ID GRCh37 Pos GRCh38 Pos
1 TP53 NM_000546.5(TP53): c.832C> A (p.Pro278Thr) single nucleotide variant Likely pathogenic,drug response rs17849781 17:7577106-7577106 17:7673788-7673788
2 TP53 NM_000546.5(TP53): c.818G> T (p.Arg273Leu) single nucleotide variant Pathogenic rs28934576 17:7577120-7577120 17:7673802-7673802
3 TP53 NM_000546.5(TP53): c.517G> T (p.Val173Leu) single nucleotide variant Pathogenic rs876660754 17:7578413-7578413 17:7675095-7675095
4 TP53 NM_000546.5(TP53): c.712T> C (p.Cys238Arg) single nucleotide variant Pathogenic rs1057519981 17:7577569-7577569 17:7674251-7674251
5 TP53 NM_000546.5(TP53): c.713G> T (p.Cys238Phe) single nucleotide variant Pathogenic rs730882005 17:7577568-7577568 17:7674250-7674250
6 TP53 NM_000546.5(TP53): c.841G> T (p.Asp281Tyr) single nucleotide variant Pathogenic rs764146326 17:7577097-7577097 17:7673779-7673779
7 TP53 NM_000546.5(TP53): c.841G> A (p.Asp281Asn) single nucleotide variant Pathogenic rs764146326 17:7577097-7577097 17:7673779-7673779
8 TP53 NM_000546.5(TP53): c.537T> G (p.His179Gln) single nucleotide variant Pathogenic rs876660821 17:7578393-7578393 17:7675075-7675075
9 TP53 NM_000546.5(TP53): c.742C> T (p.Arg248Trp) single nucleotide variant Pathogenic rs121912651 17:7577539-7577539 17:7674221-7674221
10 TP53 NM_000546.5(TP53): c.733G> T (p.Gly245Cys) single nucleotide variant Pathogenic rs28934575 17:7577548-7577548 17:7674230-7674230
11 TP53 NM_000546.5(TP53): c.734G> A (p.Gly245Asp) single nucleotide variant Pathogenic rs121912656 17:7577547-7577547 17:7674229-7674229
12 MAP2K2 NM_030662.3(MAP2K2): c.169T> G (p.Phe57Val) single nucleotide variant Pathogenic rs121434498 19:4117551-4117551 19:4117553-4117553
13 SMAD4 NM_005359.5(SMAD4): c.1081C> T (p.Arg361Cys) single nucleotide variant Pathogenic rs80338963 18:48591918-48591918 18:51065548-51065548
14 TP53 NM_000546.5(TP53): c.733G> A (p.Gly245Ser) single nucleotide variant Pathogenic rs28934575 17:7577548-7577548 17:7674230-7674230
15 TP53 NM_000546.5(TP53): c.659A> C (p.Tyr220Ser) single nucleotide variant Pathogenic rs121912666 17:7578190-7578190 17:7674872-7674872
16 HRAS NM_005343.4(HRAS): c.34G> A (p.Gly12Ser) single nucleotide variant Pathogenic rs104894229 11:534289-534289 11:534289-534289
17 HRAS NM_005343.4(HRAS): c.35G> C (p.Gly12Ala) single nucleotide variant Pathogenic rs104894230 11:534288-534288 11:534288-534288
18 HRAS NM_005343.4(HRAS): c.37G> T (p.Gly13Cys) single nucleotide variant Pathogenic rs104894228 11:534286-534286 11:534286-534286
19 HRAS NM_005343.4(HRAS): c.34G> T (p.Gly12Cys) single nucleotide variant Pathogenic rs104894229 11:534289-534289 11:534289-534289
20 PIK3CA NM_006218.4(PIK3CA): c.3140A> G (p.His1047Arg) single nucleotide variant Pathogenic rs121913279 3:178952085-178952085 3:179234297-179234297
21 PIK3CA NM_006218.4(PIK3CA): c.3140A> T (p.His1047Leu) single nucleotide variant Pathogenic rs121913279 3:178952085-178952085 3:179234297-179234297
22 PIK3CA NM_006218.4(PIK3CA): c.1634A> C (p.Glu545Ala) single nucleotide variant Pathogenic rs121913274 3:178936092-178936092 3:179218304-179218304
23 SMAD4 NM_005359.5(SMAD4): c.1082G> A (p.Arg361His) single nucleotide variant Pathogenic rs377767347 18:48591919-48591919 18:51065549-51065549
24 PIK3CA NM_006218.4(PIK3CA): c.3139C> T (p.His1047Tyr) single nucleotide variant Pathogenic rs121913281 3:178952084-178952084 3:179234296-179234296
25 TP53 NM_000546.5(TP53): c.488A> G (p.Tyr163Cys) single nucleotide variant Pathogenic rs148924904 17:7578442-7578442 17:7675124-7675124
26 TP53 NM_000546.5(TP53): c.659A> G (p.Tyr220Cys) single nucleotide variant Pathogenic rs121912666 17:7578190-7578190 17:7674872-7674872
27 TP53 NM_000546.5(TP53): c.638G> A (p.Arg213Gln) single nucleotide variant Pathogenic rs587778720 17:7578211-7578211 17:7674893-7674893
28 TP53 NM_000546.5(TP53): c.422G> A (p.Cys141Tyr) single nucleotide variant Pathogenic rs587781288 17:7578508-7578508 17:7675190-7675190
29 TP53 NM_000546.5(TP53): c.844C> G (p.Arg282Gly) single nucleotide variant Pathogenic rs28934574 17:7577094-7577094 17:7673776-7673776
30 TP53 NM_000546.5(TP53): c.842A> G (p.Asp281Gly) single nucleotide variant Pathogenic rs587781525 17:7577096-7577096 17:7673778-7673778
31 TP53 NM_000546.5(TP53): c.706T> G (p.Tyr236Asp) single nucleotide variant Pathogenic rs587782289 17:7577575-7577575 17:7674257-7674257
32 TP53 NM_000546.5(TP53): c.856G> A (p.Glu286Lys) single nucleotide variant Pathogenic rs786201059 17:7577082-7577082 17:7673764-7673764
33 TP53 NM_000546.5(TP53): c.584T> C (p.Ile195Thr) single nucleotide variant Pathogenic rs760043106 17:7578265-7578265 17:7674947-7674947
34 TP53 NM_000546.5(TP53): c.833C> T (p.Pro278Leu) single nucleotide variant Pathogenic rs876659802 17:7577105-7577105 17:7673787-7673787
35 TP53 NM_000546.5(TP53): c.818G> C (p.Arg273Pro) single nucleotide variant Pathogenic/Likely pathogenic rs28934576 17:7577120-7577120 17:7673802-7673802
36 TP53 NM_000546.5(TP53): c.824G> A (p.Cys275Tyr) single nucleotide variant Pathogenic/Likely pathogenic rs863224451 17:7577114-7577114 17:7673796-7673796
37 TP53 NM_000546.5(TP53): c.517G> A (p.Val173Met) single nucleotide variant Pathogenic/Likely pathogenic rs876660754 17:7578413-7578413 17:7675095-7675095
38 PIK3CA NM_006218.4(PIK3CA): c.1635G> T (p.Glu545Asp) single nucleotide variant Pathogenic/Likely pathogenic rs121913275 3:178936093-178936093 3:179218305-179218305
39 TP53 NM_000546.5(TP53): c.638G> C (p.Arg213Pro) single nucleotide variant Pathogenic/Likely pathogenic rs587778720 17:7578211-7578211 17:7674893-7674893
40 TP53 NM_000546.5(TP53): c.842A> T (p.Asp281Val) single nucleotide variant Pathogenic/Likely pathogenic rs587781525 17:7577096-7577096 17:7673778-7673778
41 TP53 NM_000546.5(TP53): c.527G> A (p.Cys176Tyr) single nucleotide variant Pathogenic/Likely pathogenic rs786202962 17:7578403-7578403 17:7675085-7675085
42 GNAS NM_001077488.4(GNAS): c.605G> T (p.Arg202Leu) single nucleotide variant Pathogenic/Likely pathogenic rs121913495 20:57484421-57484421 20:58909366-58909366
43 PIK3CA NM_006218.4(PIK3CA): c.353G> A (p.Gly118Asp) single nucleotide variant Pathogenic/Likely pathogenic rs587777790 3:178917478-178917478 3:179199690-179199690
44 PIK3CA NM_006218.4(PIK3CA): c.3129G> A (p.Met1043Ile) single nucleotide variant Pathogenic/Likely pathogenic rs121913283 3:178952074-178952074 3:179234286-179234286
45 HRAS NM_005343.4(HRAS): c.38G> T (p.Gly13Val) single nucleotide variant Pathogenic/Likely pathogenic rs104894226 11:534285-534285 11:534285-534285
46 TP53 NM_000546.5(TP53): c.451C> T (p.Pro151Ser) single nucleotide variant Pathogenic/Likely pathogenic rs28934874 17:7578479-7578479 17:7675161-7675161
47 TP53 NM_000546.5(TP53): c.701A> G (p.Tyr234Cys) single nucleotide variant Pathogenic/Likely pathogenic rs587780073 17:7577580-7577580 17:7674262-7674262
48 TP53 NM_000546.5(TP53): c.535C> T (p.His179Tyr) single nucleotide variant Pathogenic/Likely pathogenic rs587780070 17:7578395-7578395 17:7675077-7675077
49 KRAS NM_004985.5(KRAS): c.183A> T (p.Gln61His) single nucleotide variant Pathogenic/Likely pathogenic rs17851045 12:25380275-25380275 12:25227341-25227341
50 HRAS NM_005343.4(HRAS): c.37G> C (p.Gly13Arg) single nucleotide variant Pathogenic/Likely pathogenic rs104894228 11:534286-534286 11:534286-534286
Sources

Expression for Pancreatic Adenocarcinoma

About this section
Search GEO for disease gene expression data for Pancreatic Adenocarcinoma.
Sources

Pathways for Pancreatic Adenocarcinoma

About this section

Pathways related to Pancreatic Adenocarcinoma according to GeneCards Suite gene sharing:

(show top 50) (show all 255)
# Super pathways Score Top Affiliating Genes
1
Signaling by GPCR 66
Show member pathways
 14.4 VEGFA TP53 STAT3 SRC SMAD4 PIK3CA
2
Innate Immune System 66
Show member pathways
 14.26 VEGFA TP53 STAT3 SRC PTGS2 PIK3CA
3
ERK Signaling 64
Show member pathways
 14.09 VEGFA TP53 STAT3 SRC SMAD4 PTGS2
4
Apoptotic Pathways in Synovial Fibroblasts 64
Show member pathways
 14.06 TP53 SRC MAP2K2 KRAS HRAS GNAS
5
HIV Life Cycle 66
Show member pathways
 13.97 STAT3 SRC SMAD4 PIK3CA MUC4 MAP2K2
6
PEDF Induced Signaling 64
Show member pathways
 13.93 TP53 STAT3 SRC SMAD4 PTGS2 MAP2K2
7
GPCR Pathway 64
Show member pathways
 13.93 VEGFA TP53 STAT3 SRC SMAD4 PTGS2
8
TGF-Beta Pathway 64
Show member pathways
 13.81 VEGFA TP53 STAT3 SRC SMAD4 PIK3CA
9
Activation of cAMP-Dependent PKA 64
Show member pathways
 13.8 SRC SMAD4 MAP2K2 KRAS HRAS GNAS
10
Developmental Biology 66
Show member pathways
 13.77 VEGFA STAT3 SRC SMAD4 PIK3CA MAP2K2
11
Integrin Pathway 64
Show member pathways
 13.68 VEGFA STAT3 SRC PIK3CA MAP2K2 KRAS
12
Class I MHC mediated antigen processing and presentation 66
Show member pathways
 13.67 TP53 SRC PIK3CA KRAS HRAS ERBB2
13
Akt Signaling 64
Show member pathways
 13.67 TP53 STAT3 SRC KRAS HRAS GNAS
14
Cytokine Signaling in Immune system 66
Show member pathways
 13.62 VEGFA TP53 STAT3 SRC PTGS2 PIK3CA
15
CREB Pathway 64
Show member pathways
 13.56 SRC MAP2K2 KRAS HRAS GNAS ERBB2
16
Response to elevated platelet cytosolic Ca2+ 66
Show member pathways
 13.55 VEGFA TP53 SRC PIK3CA KRAS HRAS
17
Nanog in Mammalian ESC Pluripotency 64
Show member pathways
 13.55 VEGFA SRC MAP2K2 KRAS HRAS GNAS
18
PAK Pathway 64
Show member pathways
 13.54 SRC SMAD4 KRAS HRAS ERBB2 EGFR
19
IL-2 Pathway 64
Show member pathways
 13.51 TP53 STAT3 SRC MAP2K2 KRAS HRAS
20
Phospholipase-C Pathway 64
Show member pathways
 13.34 TP53 SRC MAP2K2 KRAS HRAS GNAS
21
DAG and IP3 signaling 66
Show member pathways
 13.33 SRC SMAD4 PTGS2 KRAS HRAS GNAS
22
p70S6K Signaling 64
Show member pathways
 13.33 STAT3 PTGS2 MAP2K2 KRAS HRAS GNAS
23
G-Beta Gamma Signaling 64
Show member pathways
 13.33 VEGFA SRC PTGS2 MAP2K2 KRAS HRAS
24
Circadian entrainment 37
Show member pathways
 13.31 VEGFA SRC PIK3CA MAP2K2 KRAS HRAS
25
fMLP Pathway 64
Show member pathways
 13.31 VEGFA TP53 STAT3 SRC MAP2K2 KRAS
26
TNFR1 Pathway 64
Show member pathways
 13.25 VEGFA TP53 SRC PIK3CA MAP2K2 KRAS
27
TCR Signaling (Qiagen) 64
Show member pathways
 13.21 TP53 STAT3 SRC PTGS2 MAP2K2 KRAS
28
Regulation of lipid metabolism Insulin signaling-generic cascades 22
Show member pathways
 13.21 VEGFA STAT3 SRC PIK3CA MAP2K2 KRAS
29
Development Angiotensin activation of ERK 22
Show member pathways
 13.2 TP53 SRC PIK3CA MAP2K2 KRAS HRAS
30
NFAT and Cardiac Hypertrophy 64
Show member pathways
 13.18 STAT3 SRC PIK3CA MAP2K2 KRAS HRAS
31
CCR5 Pathway in Macrophages 64
Show member pathways
 13.16 STAT3 SRC PIK3CA KRAS HRAS GNAS
32
Sertoli-Sertoli Cell Junction Dynamics 64
Show member pathways
 13.11 SRC MAP2K2 KRAS HRAS CTNNB1 AKT1
33
PI3K-Akt signaling pathway 37
Show member pathways
 13.11 VEGFA TP53 PTGS2 PIK3CA MAP2K2 KRAS
34
MAPK signaling pathway 37 1
13.07 VEGFA TP53 MAP2K2 KRAS HRAS ERBB2
35
Apoptosis Modulation and Signaling 1
Show member pathways
 13.06 TP53 PIK3CA MAP2K2 KRAS HRAS CDKN2A
36
Beta-Adrenergic Signaling 64
Show member pathways
 13.06 SRC MAP2K2 KRAS HRAS GNAS CTNNB1
37
Common Cytokine Receptor Gamma-Chain Family Signaling Pathways 65
Show member pathways
 13.04 STAT3 PIK3CA MAP2K2 KRAS HRAS CCND1
38
Downstream signaling events of B Cell Receptor (BCR) 66
Show member pathways
 13.04 TP53 SRC PIK3CA KRAS HRAS ERBB2
39
Ras signaling pathway 37
Show member pathways
 13.04 VEGFA SRC PIK3CA MAP2K2 KRAS HRAS
40
MAPK-Erk Pathway 67
Show member pathways
 13.03 STAT3 SRC PIK3CA MAP2K2 KRAS HRAS
41
Development HGF signaling pathway 22
Show member pathways
 13.02 TP53 STAT3 SRC PTGS2 PIK3CA MAP2K2
42
G-AlphaQ Signaling 64
Show member pathways
 12.99 STAT3 SRC MAP2K2 KRAS HRAS GNAS
43
4-1BB Pathway 64
Show member pathways
 12.98 TP53 STAT3 MAP2K2 KRAS HRAS EGFR
44
Focal Adhesion 37 1
Show member pathways
 12.98 VEGFA STAT3 SRC PTGS2 PIK3CA MAP2K2
45
Development Endothelin-1/EDNRA signaling 22
Show member pathways
 12.97 VEGFA SRC PIK3CA MAP2K2 KRAS HRAS
46
Human cytomegalovirus infection 37
Show member pathways
 12.95 VEGFA TP53 STAT3 SRC SMAD4 PTGS2
47
Gastric cancer 37
Show member pathways
 12.92 TP53 SMAD4 PIK3CA MAP2K2 KRAS HRAS
48
Regulation of actin cytoskeleton 37 1
12.91 SRC PIK3CA MAP2K2 KRAS HRAS EGFR
49
Immune response Fc epsilon RI pathway 22
Show member pathways
 12.9 VEGFA SRC PTGS2 PIK3CA MAP2K2 KRAS
50
Development Dopamine D2 receptor transactivation of EGFR 22
Show member pathways
 12.9 STAT3 SRC PIK3CA MAP2K2 HRAS GNAS
Sources

GO Terms for Pancreatic Adenocarcinoma

About this section

Cellular components related to Pancreatic Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein-containing complex GO:0032991 9.8 TP53 PTGS2 EGFR CTNNB1 BRCA2 AKT1
2 cytosol GO:0005829 9.8 TP53 STAT3 SRC SMAD4 PIK3CA MAP2K2
3 perinuclear region of cytoplasm GO:0048471 9.7 SRC MAP2K2 HRAS GNAS ERBB2 EGFR
4 cytoplasm GO:0005737 9.58 VEGFA TP53 STAT3 SRC SMAD4 PTGS2
5 nucleus GO:0005634 10.21 TP53 STAT3 SRC SMAD4 MAP2K2 HRAS
6 membrane GO:0016020 10.16 VEGFA TP53 SRC PTGS2 PIK3CA MUC4

Biological processes related to Pancreatic Adenocarcinoma according to GeneCards Suite gene sharing:

(show top 50) (show all 76)
# Name GO ID Score Top Affiliating Genes
1 response to organic cyclic compound GO:0014070 9.99 STAT3 PTGS2 EGFR CCND1
2 response to organic substance GO:0010033 9.97 STAT3 PTGS2 CCND1 AKT1
3 cellular response to hypoxia GO:0071456 9.97 VEGFA TP53 SRC PTGS2 AKT1
4 cytokine-mediated signaling pathway GO:0019221 9.97 VEGFA TP53 STAT3 PTGS2 PIK3CA KRAS
5 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.96 VEGFA TP53 SRC EGF
6 liver development GO:0001889 9.96 PIK3CA KRAS EGFR CCND1
7 positive regulation of protein phosphorylation GO:0001934 9.95 VEGFA KRAS HRAS ERBB2 EGFR CCND1
8 negative regulation of cysteine-type endopeptidase activity involved in apoptotic process GO:0043154 9.94 VEGFA SRC PTGS2 AKT1
9 Ras protein signal transduction GO:0007265 9.94 TP53 KRAS HRAS CDKN2A
10 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.93 SRC HRAS EGFR
11 positive regulation of cell growth GO:0030307 9.92 ERBB2 EGFR AKT1
12 cellular response to mechanical stimulus GO:0071260 9.92 PTGS2 EGFR AKT1
13 stimulatory C-type lectin receptor signaling pathway GO:0002223 9.92 SRC MUC4 KRAS HRAS
14 response to glucocorticoid GO:0051384 9.91 PTGS2 KRAS CCND1
15 positive regulation of epithelial cell proliferation GO:0050679 9.91 VEGFA HRAS ERBB2 EGFR
16 cellular response to growth factor stimulus GO:0071363 9.91 ERBB2 EGFR CTNNB1 AKT1
17 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.91 VEGFA PTGS2 PIK3CA EGFR AKT1
18 vascular endothelial growth factor receptor signaling pathway GO:0048010 9.9 VEGFA SRC PIK3CA
19 positive regulation of smooth muscle cell proliferation GO:0048661 9.9 PTGS2 EGFR AKT1
20 negative regulation of neuron death GO:1901215 9.9 STAT3 CTNNB1 AKT1
21 T cell costimulation GO:0031295 9.89 SRC PIK3CA AKT1
22 positive regulation of cell adhesion GO:0045785 9.89 VEGFA SRC ERBB2
23 cellular response to epidermal growth factor stimulus GO:0071364 9.88 ERBB2 EGFR AKT1
24 epidermal growth factor receptor signaling pathway GO:0007173 9.88 SRC PIK3CA EGFR EGF AKT1
25 negative regulation of Notch signaling pathway GO:0045746 9.87 EGFR EGF AKT1
26 positive regulation of MAPK cascade GO:0043410 9.87 HRAS ERBB2 CTNNB1
27 cellular response to reactive oxygen species GO:0034614 9.86 SRC EGFR AKT1
28 phosphatidylinositol 3-kinase signaling GO:0014065 9.86 PIK3CA ERBB2 AKT1
29 positive regulation of vasoconstriction GO:0045907 9.86 PTGS2 EGFR AKT1
30 regulation of cell motility GO:2000145 9.85 ERBB2 EGFR EGF
31 cell aging GO:0007569 9.85 TP53 HRAS BRCA2
32 ERBB2 signaling pathway GO:0038128 9.83 PIK3CA ERBB2 EGFR EGF
33 response to estradiol GO:0032355 9.83 STAT3 PTGS2 EGFR CTNNB1 CCND1
34 mammary gland alveolus development GO:0060749 9.82 VEGFA EGF CCND1
35 positive regulation of production of miRNAs involved in gene silencing by miRNA GO:1903800 9.76 TP53 MAP2K2 EGFR
36 cell proliferation GO:0008283 9.76 TP53 STAT3 SRC SMAD4 EGFR CTNNB1
37 response to leptin GO:0044321 9.75 STAT3 CCND1
38 regulation of mitochondrial membrane permeability GO:0046902 9.75 TP53 STAT3
39 negative regulation of telomerase activity GO:0051974 9.74 TP53 SRC
40 anoikis GO:0043276 9.74 PIK3CA AKT1
41 positive regulation of glucose metabolic process GO:0010907 9.74 SRC AKT1
42 regulation of protein localization to cell surface GO:2000008 9.74 EGF CTNNB1
43 regulation of calcium ion import GO:0090279 9.73 EGF CTNNB1
44 mitotic G1 DNA damage checkpoint GO:0031571 9.73 TP53 CCND1
45 entry of bacterium into host cell GO:0035635 9.73 SRC CTNNB1
46 response to isolation stress GO:0035900 9.73 KRAS HRAS
47 regulation of early endosome to late endosome transport GO:2000641 9.72 SRC MAP2K2
48 negative regulation of immature T cell proliferation in thymus GO:0033088 9.71 ERBB2 CDKN2A
49 hair follicle placode formation GO:0060789 9.71 GNAS CTNNB1
50 negative regulation of ERBB signaling pathway GO:1901185 9.71 ERBB2 EGFR EGF

Molecular functions related to Pancreatic Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 17)
# Name GO ID Score Top Affiliating Genes
1 protein kinase activity GO:0004672 9.99 SRC MAP2K2 ERBB2 EGFR CCND1 AKT1
2 kinase activity GO:0016301 9.98 SRC PIK3CA MAP2K2 ERBB2 EGFR CCND1
3 protein heterodimerization activity GO:0046982 9.97 VEGFA TP53 SMAD4 ERBB2 EGFR CTNNB1
4 transcription factor binding GO:0008134 9.93 TP53 STAT3 CTNNB1 CDKN2A CCND1
5 nucleotide binding GO:0000166 9.85 MAP2K2 KRAS HRAS ERBB2 EGFR
6 protein C-terminus binding GO:0008022 9.8 SRC HRAS ERBB2 CTNNB1 BRCA2
7 enzyme binding GO:0019899 9.8 TP53 SRC PTGS2 EGFR CTNNB1 CCND1
8 RNA polymerase II transcription factor binding GO:0001085 9.72 TP53 SMAD4 CTNNB1
9 disordered domain specific binding GO:0097718 9.7 TP53 CTNNB1 CDKN2A
10 protein tyrosine kinase activity GO:0004713 9.67 SRC MAP2K2 ERBB2 EGFR
11 I-SMAD binding GO:0070411 9.57 SMAD4 CTNNB1
12 nitric-oxide synthase regulator activity GO:0030235 9.56 EGFR AKT1
13 protein phosphatase binding GO:0019903 9.55 TP53 STAT3 ERBB2 EGFR CTNNB1
14 protein kinase binding GO:0019901 9.23 TP53 STAT3 SRC EGFR CTNNB1 CDKN2A
15 phosphatidylinositol-4,5-bisphosphate 3-kinase activity GO:0046934 8.65 PIK3CA
16 protein binding GO:0005515 10.3 VEGFA TP53 STAT3 SRC SMAD4 PTGS2
17 identical protein binding GO:0042802 10.08 VEGFA TP53 STAT3 SMAD4 ERBB2 EGFR
Sources

Sources for Pancreatic Adenocarcinoma

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....